| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis
|
Deng, Guofang
|
|
|
24 |
9 |
p. 940-941
|
article
|
| 2 |
Accelerating antibiotic access and stewardship: a new model to safeguard public health
|
Cohn, Jennifer
|
|
|
24 |
9 |
p. e584-e590
|
article
|
| 3 |
Alarming Plasmodium falciparum resistance to artemisinin-based combination therapy in Africa: the critical role of the partner drug
|
Björkman, Anders
|
|
|
24 |
9 |
p. e540-e541
|
article
|
| 4 |
Amanda Kvalsvig—from paediatrics to epidemiology
|
Kirby, Tony
|
|
|
24 |
9 |
p. 951
|
article
|
| 5 |
Anthony Fauci: a life on page
|
Adhikari, Bipin
|
|
|
24 |
9 |
p. 952
|
article
|
| 6 |
Artificial intelligence to transform public health in Africa
|
Tanui, Collins Kipngetich
|
|
|
24 |
9 |
p. e542
|
article
|
| 7 |
Asymptomatic parasitemia and RTS,S vaccine efficacy
|
Arisue, Nobuko
|
|
|
24 |
9 |
p. 942-944
|
article
|
| 8 |
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
|
Cevik, Muge
|
|
|
24 |
9 |
p. 1003-1014
|
article
|
| 9 |
Brazil to distribute paediatric antimalarial in Amazon
|
Bagcchi, Sanjeet
|
|
|
24 |
9 |
p. e550
|
article
|
| 10 |
Chad eliminates gambiense sleeping sickness
|
Boisson-Walsh, Alix
|
|
|
24 |
9 |
p. e551
|
article
|
| 11 |
Correction to Lancet Infect Dis 2022; 22: 265–73
|
|
|
|
24 |
9 |
p. e549
|
article
|
| 12 |
Correction to Lancet Infect Dis 2024; published online May 31. https://doi.org/10.1016/S1473-3099(24)00221-4
|
|
|
|
24 |
9 |
p. e549
|
article
|
| 13 |
Correction to Lancet Infect Dis 2024; published online May 31. https://doi.org/10.1016/S1473-3099(24)00221-4
|
|
|
|
24 |
9 |
p. e549
|
article
|
| 14 |
Emergence of an extensively drug-resistant Neisseria gonorrhoeae clone
|
van Hal, Sebastiaan J
|
|
|
24 |
9 |
p. e547-e548
|
article
|
| 15 |
Field evaluation of validity and feasibility of Pan-Lassa rapid diagnostic test for Lassa fever in Abakaliki, Nigeria: a prospective diagnostic accuracy study
|
Elsinga, Jelte
|
|
|
24 |
9 |
p. 1037-1044
|
article
|
| 16 |
First report from the UK COVID-19 Inquiry
|
Burki, Talha
|
|
|
24 |
9 |
p. e555-e556
|
article
|
| 17 |
Genotypic analysis of RTS,S/AS01E malaria vaccine efficacy against parasite infection as a function of dosage regimen and baseline malaria infection status in children aged 5–17 months in Ghana and Kenya: a longitudinal phase 2b randomised controlled trial
|
Juraska, Michal
|
|
|
24 |
9 |
p. 1025-1036
|
article
|
| 18 |
Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021
|
|
|
|
24 |
9 |
p. 974-1002
|
article
|
| 19 |
Global Sanitation Summit 2024
|
Das, Manjulika
|
|
|
24 |
9 |
p. e552
|
article
|
| 20 |
Identifying efficacious SARS-CoV-2 antivirals in a changing immune landscape
|
Visser, Leo G
|
|
|
24 |
9 |
p. 936
|
article
|
| 21 |
Immune evasiveness of SARS-CoV-2 variants and vaccine selection
|
Inghammar, Malin
|
|
|
24 |
9 |
p. 937-938
|
article
|
| 22 |
Infectious disease surveillance update
|
Ramgolam, Aimee
|
|
|
24 |
9 |
p. e557
|
article
|
| 23 |
Limited progress towards immunisation targets in 2023
|
Jesudason, Timothy
|
|
|
24 |
9 |
p. e553
|
article
|
| 24 |
Long-term efficacy and immunogenicity of Ad26.RSV.preF–RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study
|
Falsey, Ann R
|
|
|
24 |
9 |
p. 1015-1024
|
article
|
| 25 |
Mortality of H5N1 human infections might be due to H5N1 virus pneumonia and could decrease by switching receptor
|
Granata, Guido
|
|
|
24 |
9 |
p. e544-e545
|
article
|
| 26 |
Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies
|
Bézay, Nicole
|
|
|
24 |
9 |
p. 1045-1058
|
article
|
| 27 |
Oropouche fever, the mysterious threat
|
The Lancet Infectious Diseases,
|
|
|
24 |
9 |
p. 935
|
article
|
| 28 |
Phyllis Dako-Gyeke
|
Bagcchi, Sanjeet
|
|
|
24 |
9 |
p. 950
|
article
|
| 29 |
Rapid diagnostic tests for Lassa fever: what do we aim for?
|
Groger, Mirjam
|
|
|
24 |
9 |
p. 944-945
|
article
|
| 30 |
Recombination as an evolutionary driver of MERS-related coronavirus emergence
|
Tolentino, Jarel Elgin
|
|
|
24 |
9 |
p. e546
|
article
|
| 31 |
Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study
|
Moustsen-Helms, Ida Rask
|
|
|
24 |
9 |
p. 964-973
|
article
|
| 32 |
Research in brief
|
Venkatesan, Priya
|
|
|
24 |
9 |
p. e558
|
article
|
| 33 |
Setbacks and advances in the global HIV response
|
Holt, Ed
|
|
|
24 |
9 |
p. e554
|
article
|
| 34 |
Strongyloides stercoralis hyperinfection syndrome
|
Jacob, Lemna
|
|
|
24 |
9 |
p. e601
|
article
|
| 35 |
Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)
|
Wongnak, Phrutsamon
|
|
|
24 |
9 |
p. 953-963
|
article
|
| 36 |
The emergence of artemisinin partial resistance in Africa: how do we respond?
|
Rosenthal, Philip J
|
|
|
24 |
9 |
p. e591-e600
|
article
|
| 37 |
The epidemiology, transmission, diagnosis, and management of drug-resistant tuberculosis—lessons from the South African experience
|
Naidoo, Kogieleum
|
|
|
24 |
9 |
p. e559-e575
|
article
|
| 38 |
The long-term efficacy of a respiratory syncytial virus vaccine for older adults
|
Sande, Charles J
|
|
|
24 |
9 |
p. 941-942
|
article
|
| 39 |
The potential role of the 4CMenB vaccine in combating gonorrhoea: the need for nuance in interpreting the DOXYVAC trial
|
White, Peter J
|
|
|
24 |
9 |
p. e543
|
article
|
| 40 |
Unveiling the viral aetiologies of lower respiratory infections
|
Li, You
|
|
|
24 |
9 |
p. 938-939
|
article
|
| 41 |
Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK
|
Ladhani, Shamez N
|
|
|
24 |
9 |
p. e576-e583
|
article
|
| 42 |
Vaccination hesistancy in Lyme borreliosis
|
Dattwyler, Raymond J
|
|
|
24 |
9 |
p. 945-947
|
article
|
| 43 |
Waiting is no longer an option for household contacts of people with drug-resistant tuberculosis
|
Pannikottu, Jean
|
|
|
24 |
9 |
p. 947-949
|
article
|
Journal description